FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

NCT07515963 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Colo-rectal Cancer

Interventions

DRUG: FULIRI combination targeted therapy

Sponsor

Zhongnan Hospital